Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC.
Benefit seen across PD-L1 groups.
Dual target strategy keeps moving, VEGF still matters.”
Erika Hamilton, Chair of the Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared this post, adding:
“This class of drugs is going broadly into multiple other tumor types/histologies. Exciting to see what may be possible with PD-1/VEGFs (multiple ones) and the PD-L1/VEGF.
Especially in tumors that have had ‘less benefit’ to the immune.”
Follow the latest ESMO 2025 news on OncoDaily.
